|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5,470.00 KRW | +4.59% |
|
+12.44% | -19.79% |
| 12-09 | GC Genome Study Identifies 'Confounders' Interfering with Cancer Signals to Improve Liquid Biopsy Accuracy | CI |
| 25-06-12 | GC Genome Shares Decline Nearly 3% After Strong Kosdaq Debut | MT |
Business description: GC Genome Corporation

Executive Committee: GC Genome Corporation
| Manager | Title | Age | Since |
|---|---|---|---|
Chang-Seok Gi
CEO | Chief Executive Officer | 57 | 2020-03-25 |
Sang-Hun Jeong
DFI | Director of Finance/CFO | 50 | 2025-03-26 |
Seu-Nga Hyun
AUD | Comptroller/Controller/Auditor | 45 | 2024-03-28 |
Eun-Hae Jo
PRN | Corporate Officer/Principal | 52 | - |
Composition of the Board of Directors: GC Genome Corporation
| Director | Title | Age | Since |
|---|---|---|---|
Sang-Uk Kim
BRD | Director/Board Member | 57 | 2023-03-29 |
Company details: GC Genome Corporation

Medical & Diagnostic Laboratories
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +4.59% | +12.44% | -32.22% | - | 87.76M | ||
| -1.16% | +17.75% | +109.51% | +496.83% | 46.43B | ||
| +0.67% | +4.52% | +20.86% | +50.13% | 25.88B | ||
| +0.67% | +2.56% | -19.02% | -34.64% | 7.76B | ||
| +6.76% | +15.69% | +44.83% | +142.18% | 5.69B | ||
| +1.16% | +2.82% | +22.50% | +65.56% | 3.39B | ||
| +1.04% | +14.77% | -25.92% | +1,363.91% | 2.3B | ||
| +0.36% | +4.99% | +186.72% | +17.90% | 2.13B | ||
| +6.83% | +12.50% | +2.48% | -51.72% | 1.99B | ||
| +4.04% | +20.05% | +33.80% | -8.01% | 1.84B | ||
| Average | +2.50% | +8.13% | +34.35% | +226.91% | 9.75B | |
| Weighted average by Cap. | +0.37% | +9.95% | +63.69% | +289.31% |
Sector
Annual profits - Rate of surprise
- Stock Market
- Stocks
- A340450 Stock
- Company GC Genome Corporation
Select your edition
All financial news and data tailored to specific country editions

















